Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTART: Apalutamide and ADT with or without Radiation in Recurrent Prostate Cancer
NCT04585932Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Planned start Nov 2020; status: withdrawn.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04585932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585932.